Ming‐Chung Wang

1.6k total citations
47 papers, 584 citations indexed

About

Ming‐Chung Wang is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Ming‐Chung Wang has authored 47 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 17 papers in Hematology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Ming‐Chung Wang's work include Lymphoma Diagnosis and Treatment (14 papers), Viral-associated cancers and disorders (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Ming‐Chung Wang is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Viral-associated cancers and disorders (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Ming‐Chung Wang collaborates with scholars based in Taiwan, United States and Japan. Ming‐Chung Wang's co-authors include Ching‐Yuan Kuo, Ming‐Chun Ma, Sung‐Nan Pei, Chien‐Hung Chen, Chuan–Mo Lee, Tsung‐Hui Hu, Wan‐Ting Huang, Huey‐Ling You, Jien-Wei Liu and Chun‐Chih Chien and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Ming‐Chung Wang

44 papers receiving 573 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ming‐Chung Wang Taiwan 12 218 194 164 124 96 47 584
Tomoteru Kamimura Japan 16 409 1.9× 431 2.2× 88 0.5× 39 0.3× 79 0.8× 54 747
Wai Yip Lam Hong Kong 11 628 2.9× 389 2.0× 102 0.6× 37 0.3× 48 0.5× 14 877
Motohiro Shindo Japan 13 147 0.7× 278 1.4× 85 0.5× 262 2.1× 32 0.3× 54 776
Nóra Schweitzer Germany 18 295 1.4× 254 1.3× 205 1.3× 36 0.3× 45 0.5× 34 960
B. Süßkind United States 17 113 0.5× 311 1.6× 145 0.9× 78 0.6× 23 0.2× 40 1.3k
Yuxian Huang China 18 632 2.9× 429 2.2× 140 0.9× 59 0.5× 31 0.3× 78 1.1k
Takuya Matsumura Japan 14 237 1.1× 242 1.2× 134 0.8× 50 0.4× 91 0.9× 20 734
Hua‐Guo Xu China 16 379 1.7× 321 1.7× 94 0.6× 44 0.4× 28 0.3× 62 953
Maud Brandely France 12 209 1.0× 82 0.4× 128 0.8× 98 0.8× 30 0.3× 19 635
Luydson Richardson Silva Vasconcelos Brazil 13 119 0.5× 86 0.4× 33 0.2× 50 0.4× 19 0.2× 63 486

Countries citing papers authored by Ming‐Chung Wang

Since Specialization
Citations

This map shows the geographic impact of Ming‐Chung Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Chung Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Chung Wang more than expected).

Fields of papers citing papers by Ming‐Chung Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming‐Chung Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Chung Wang. The network helps show where Ming‐Chung Wang may publish in the future.

Co-authorship network of co-authors of Ming‐Chung Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Ming‐Chung Wang. A scholar is included among the top collaborators of Ming‐Chung Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming‐Chung Wang. Ming‐Chung Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zeidan, Amer M., Kiyoshi Ando, Odile Beyne Rauzy, et al.. (2023). Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Haematology. 11(1). e38–e50. 36 indexed citations
3.
Liu, Hsi‐Che, Ming‐Chung Kuo, Kang‐Hsi Wu, et al.. (2023). Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan. British Journal of Cancer. 128(7). 1294–1300. 5 indexed citations
4.
Kuo, Ching‐Yuan, et al.. (2023). Combination of Sarcopenia and Anemia Predicts Worse Outcome in Elderly Patients With Diffuse Large B-Cell Lymphoma. In Vivo. 37(4). 1847–1856. 3 indexed citations
5.
Chen, Ying‐Ju, Ming‐Chung Wang, Yi‐Yang Chen, et al.. (2023). Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 CALR-Mutated MPN. International Journal of Molecular Sciences. 24(10). 8747–8747.
6.
Sunami, Kazutaka, Takashi Ikeda, Shang‐Yi Huang, et al.. (2022). Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. Clinical Lymphoma Myeloma & Leukemia. 22(8). e751–e761. 5 indexed citations
7.
Kuo, Ching‐Yuan, et al.. (2022). Oral Chemotherapy Application in Elderly Patients With Diffuse Large B-Cell Lymphoma: An Alternative Regimen in Retrospective Analysis. Journal of Hematology. 11(5). 176–184. 1 indexed citations
8.
9.
Pei, Sung‐Nan, Ming‐Chung Wang, Ming‐Chun Ma, et al.. (2021). A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan. Scientific Reports. 11(1). 10069–10069. 3 indexed citations
10.
Lu, Shin-Yu, Ming‐Chun Ma, Ming‐Chung Wang, & Shui‐Sang Hsue. (2021). The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma. Journal of the Formosan Medical Association. 120(11). 1967–1976. 10 indexed citations
11.
Pan, Linlin, et al.. (2021). Differential impacts of hemolysis on coagulation parameters of blood samples. Medicine. 100(18). e25798–e25798. 4 indexed citations
12.
Liao, Chun‐Kai, et al.. (2020). Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population. Experimental and Molecular Pathology. 118. 104577–104577. 1 indexed citations
13.
Liao, Chun‐Kai, et al.. (2018). TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression. Human Pathology. 80. 145–151. 21 indexed citations
14.
15.
Chiou, Terry Ting‐Yu, Jong‐Jer Lee, Ming‐Chung Wang, et al.. (2015). Genetic disposition and modifiable factors independently associated with anemia in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 108(1). 164–169. 7 indexed citations
16.
Pei, Sung‐Nan, Ming‐Chun Ma, Huey‐Ling You, et al.. (2014). TMPRSS6 rs855791 Polymorphism Influences the Susceptibility to Iron Deficiency Anemia in Women at Reproductive Age. International Journal of Medical Sciences. 11(6). 614–619. 28 indexed citations
17.
Pei, Sung‐Nan, et al.. (2012). Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Annals of Hematology. 91(7). 1007–1012. 73 indexed citations
18.
Chen, Jingyi, Ming‐Chung Wang, & Wen‐Chun Hung. (2009). Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells. Leukemia Research. 33(11). 1520–1524. 17 indexed citations
19.
20.
Tipton, Carl L., et al.. (1973). Biosynthesis of 1,4-benzoxazin-3-ones in Zea mays. Phytochemistry. 12(2). 347–352. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoteru Kamimura Breakdown of academic impact, for papers by Wai Yip Lam Breakdown of academic impact, for papers by Motohiro Shindo Breakdown of academic impact, for papers by Nóra Schweitzer Breakdown of academic impact, for papers by B. Süßkind Breakdown of academic impact, for papers by Yuxian Huang Breakdown of academic impact, for papers by Takuya Matsumura Breakdown of academic impact, for papers by Hua‐Guo Xu Breakdown of academic impact, for papers by Maud Brandely Breakdown of academic impact, for papers by Luydson Richardson Silva Vasconcelos
Rankless by CCL
2026